2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
54
Neoplasms
38
Lung Neoplasms
25
Colorectal Neoplasms
24
Prostatic Neoplasms
17
Uterine Cervical Neoplasms
14
Motor Activity
13
Colonic Neoplasms
11
Pancreatic Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Rectal Neoplasms
9
Hematologic Neoplasms
9
Anxiety Disorders
9
Urinary Bladder Neoplasms
8
Obesity
8
Melanoma
8
Lymphoma
8
Depression
8
Ovarian Neoplasms
7
Endometrial Neoplasms
7
Vulvar Neoplasms
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Breast Carcinoma In Situ
6
Sarcoma
5
Papillomavirus Infections
5
Pain
5
Leukemia, Myeloid, Acute
5
Hematopoietic and Lymphatic System Neoplasm
5
Triple Negative Breast Neoplasms
4
Interventions
Cisplatin
12
Everolimus
10
Nivolumab
8
Etoposide
8
Temozolomide
6
Carboplatin
6
atezolizumab
5
Irinotecan
5
Ipilimumab
5
Fluorouracil
5
Bevacizumab
5
pembrolizumab
4
lutetium Lu 177 dotatate
4
Capecitabine
4
avelumab
3
Paclitaxel
3
IFL protocol
3
surufatinib
2
sintilimab
2
gallium Ga 68 dotatate
2
dostarlimab
2
cabozantinib
2
belinostat
2
azaspirane
2
Topotecan
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
Methods
×
Clear all
NCT04478175
2022-11-17
DParcoursDig
Institut Curie
Phase NA
Completed
30 enrolled